drugset / Trial / NCT02267967
Phase Ib/II Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
NaSingle-groupOpen-labelTreatment
Summary
a multicenter, open-label phase Ib study to determine the safety, tolerability and preliminary efficacy of Sulfatinib 300 mg once a day in treating advanced neuroendocrine tumors
Timeline
- Start
- 2014-10-31
- Primary completion
- 2017-08-23
- Completion
- 2017-08-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Surufatinib | Small molecule | 300 mg | Oral |